Co-Diagnostics, Inc. (NASDAQ:CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak to one of its international distributors.
According to the World Health Organization (WHO), monkeypox is a virus originally transmitted to humans from animals, and then transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding. As of July 7, 2022, over 6,000 cases of monkeypox have been reported to WHO from 59 countries.
The products shipped were designed and developed on an expedited basis to meet the demands in the distributor’s region.
Company CEO Dwight Egan commented, “The World Health Organization has stated that, ‘Detection of viral DNA by polymerase chain reaction (PCR) is the preferred laboratory test for monkeypox.’ We are grateful to our dedicated design and manufacturing teams, whose efforts have allowed us to react so quickly to meet the needs of an important distributor customer. Co-Dx is pleased to be able to continue our mission of providing high-quality, affordable molecular testing products in response to ever-changing healthcare demands in regions all around the world.”
